EE386 Cost-per-Responder Analysis of Bimekizumab (IL-17A/F Inhibitor) Against Il-17A, Il-12/23 and Il-23 Inhibitors for the Treatment of Psoriatic Arthritis in Finland
Dec 1, 2024, 00:00
10.1016/j.jval.2024.10.667
https://www.valueinhealthjournal.com/article/S1098-3015(24)03530-7/fulltext
Title :
EE386 Cost-per-Responder Analysis of Bimekizumab (IL-17A/F Inhibitor) Against Il-17A, Il-12/23 and Il-23 Inhibitors for the Treatment of Psoriatic Arthritis in Finland
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(24)03530-7&doi=10.1016/j.jval.2024.10.667
First page :
Section Title :
Open access? :
No
Section Order :
10168